NCT01174043 2023-10-13
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Indiana University
Phase 2 Completed
Clinical Trials
4 trialsNCT01664897 2020-01-07
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02355431 2019-03-08
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Incyte Corporation
Phase 2 Withdrawn
NCT00977548 2013-09-16
Erlotinib Study for Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed